Olema Oncology
Michael Wollman has extensive experience in clinical trial management, currently serving as a Contract Senior Clinical Trial Manager at Olema Oncology since December 2022. Prior roles include Contract Senior Clinical Trial Manager at Ascendis Pharma and Nektar Therapeutics, with additional experience at Pharmacyclics, Onyx Pharmaceuticals, Genentech, Sunesis Pharmaceuticals, Telik, Inc., Salmedix, Inc., and Gilead Sciences in various clinical research positions. Michael holds a Bachelor of Science degree in Biology and Psychology from Union College, earned between 1990 and 1994.
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.